



Marksans Pharma Ltd.

National Stock Exchange of India Limited
Listing Department
Exchange Plaza, C-1, Block -G
Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.

31st October, 2014

Sub: Unaudited Financial Results for the Quarter ended 30th
September, 2014 and Limited Review Report thereon

Dear Sir,

In terms of Clause 41 of the Listing Agreement, enclosed herewith kindly find Unaudited Financial Results of the Company for the Quarter ended 30th September, 2014 (both Standalone and Consolidated) approved by the Board of Directors at its meeting held today, i.e., 31st October, 2014 along with Limited Review Report thereon.

You are requested to note the above in your records.

Thanking You.

Yours faithfully,
For Marksans Pharma Limited

Harshavardhan Panigrahi
Company Secretary & Manager-Legal

Enclosed: as above

Marksans Pharma Ltd.
11th Floor, "GRANDEUR"
Opp. Gundecha Symphony
Veera Desai Extension Road,
Oshiwara, Andheri (West),
Mumbai - 400 053.

CIN : L24110MH1992PLCO66364

www.marksanspharma.com

Marksans Pharma Ltd.

Tel.: +91-22 4001 2000. Fax : +91-22 4001 2011 / 4001 2099
E-mail : info@marksanspharma.com



N. K. MITTAL & ASSOCIATES

CHARTERED ACCOUNTANTS

817, Bldg. No. 3, Navjivan Commercial Premises Co.-op. Soc., Lamington Rd., Mumbai Central (E), Mumbai - 400 008.

☎ : 2309 6121 • Mob. : 98926 40589 • E-mail : ca_mittal@rediffmail.com • nkmittalandassociates@gmail.com

N. K. Mittal

B.Com, FCA, LLB, EMBA

LIMITED REVIEW REPORT FOR THE PERIOD ENDED 30.09.2014

We have reviewed the accompanying statement of unaudited financial results of MARKSANS PHARMA LTD for the period ended 30th September, 2014 except for the disclosures regarding 'Public Shareholding' and 'Promoter and Promoter Group Shareholding' which have been traced from disclosures made by the management and have not been audited by us. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2400, *Engagements to Review Financial Statements* issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards¹ and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Clause 41 of the Listing Agreement including the manner in which it is to be disclosed, or that it contains any material misstatement.

For N. K. MITTAL & ASSOCIATES

Chartered Accountants

N.K.MITTAL

(Proprietor)

M.No.46785

Place: Mumbai

Date: 31.10.2014



UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH SEPTEMBER, 2014																	
PART 1		STANDALONE						CONSOLIDATED									
		3 MONTHS ENDED			6 MONTHS ENDED			Previous Year ended		3 MONTHS ENDED			6 MONTHS ENDED			Previous Year ended	
		30.09.2014	30.06.2014	30.09.2013	30.09.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014	30.09.2014	30.09.2013	30.09.2014	30.09.2013	30.09.2014	30.09.2013	31.03.2014	
Sr. No.	PARTICULARS	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(AUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(UNAUDITED)	(AUDITED)	
1	Income																
a)	Net Sales/ Income from Operations (Net of excise duty)	1,075.51	1,006.65	765.14	2,082.16	1,505.35	3,149.45	1,505.35	3,149.45	2,104.75	1,613.54	4,128.70	3,023.85	6,299.97	3,023.85	6,299.97	
b)	Other Operating Income					27.04	33.12	27.04	33.12	0.64	0.21	0.85	27.46	35.04	27.46	35.04	
	Total Income from operations (net)	1,075.51	1,006.65	765.14	2,082.16	1,532.39	3,182.57	1,532.39	3,182.57	2,105.39	1,613.79	4,129.55	3,051.31	6,335.01	3,051.31	6,335.01	
2	Expenses																
a)	Cost of Material Consumed	466.27	448.93	324.57	915.20	570.92	1,426.34	570.92	1,426.34	727.48	587.04	1,453.76	1,018.43	2,290.47	1,018.43	2,290.47	
b)	Purchase of Stock - in- trade	67.39	84.10	67.40	151.49	145.61	288.37	145.61	288.37	396.15	339.95	840.04	682.06	1,416.54	682.06	1,416.54	
c)	Changes in Inventories of finished goods , work-in - progress and stock- in- trade	58.97	24.49	(4.52)	83.47	11.06	(18.41)	11.06	(18.41)	58.97	24.49	(4.52)	83.47	664.41	11.06	664.41	
d)	Employee benefits expense	54.57	58.20	47.84	112.77	94.65	213.89	94.65	213.89	187.09	185.34	367.49	337.14	636.41	337.14	636.41	
e)	Depreciation and amortisation expense	21.56	22.42	22.40	43.98	44.44	86.56	44.44	86.56	39.64	31.75	80.02	63.80	156.91	63.80	156.91	
f)	Other expenses	102.39	92.92	104.77	195.32	195.66	401.09	195.66	401.09	226.11	209.42	447.24	388.18	778.95	388.18	778.95	
	Total Expenses	771.15	731.06	562.46	1,502.23	1,062.34	2,397.84	1,062.34	2,397.84	1,635.44	1,348.98	3,272.02	2,500.67	5,279.56	2,500.67	5,279.56	
3	Profit/(Loss) from operations before other income, finance costs and exceptional items (1-2)	304.36	275.59	222.68	579.93	470.05	784.73	470.05	784.73	469.95	264.81	857.53	550.64	1,055.45	550.64	1,055.45	
4	Other Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
5	Profit/(Loss) from Ordinary activities before finance costs and exceptional items(3+4)	304.36	275.59	222.68	579.93	470.05	784.73	470.05	784.73	469.95	264.81	857.53	550.64	1,055.45	550.64	1,055.45	
6	Finance cost	37.43	25.44	25.41	62.87	100.70	152.13	100.70	152.13	47.87	35.38	83.25	125.85	191.33	125.85	191.33	
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	266.93	250.15	197.27	517.06	369.35	632.60	369.35	632.60	422.08	224.87	774.28	424.79	864.12	424.79	864.12	
8	Exceptional items	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
9	Profit/(Loss) from Ordinary activities before Tax (7-8)	266.93	250.15	197.27	517.06	369.35	632.60	369.35	632.60	422.08	224.87	774.28	424.79	864.12	424.79	864.12	
10	Tax Expenses (Includes Deferred Tax & Tax for Earlier Year)	66.70	67.51	19.30	134.21	23.50	77.02	23.50	77.02	105.49	19.55	198.52	27.83	127.87	19.55	127.87	
11	Net Profit/(Loss) from Ordinary activities after tax(9-10)	200.23	182.64	177.97	382.85	345.85	555.58	345.85	555.58	316.59	205.32	575.76	396.96	736.25	396.96	736.25	
12	Less: Extraordinary item	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	Net Profit/ (Loss) for the period (11-12)	200.23	182.64	177.97	382.85	345.85	555.58	345.85	555.58	316.59	205.32	575.76	396.96	736.25	396.96	736.25	
14	Share of Profit/(Loss) of associates	-	-	-	-	-	-	-	-	4.96	5.21	9.44	9.02	17.17	9.02	17.17	
15	Minority Interest	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	Net Profit/(Loss) after taxes, minority interest and share of associates(13-14-15)	200.23	182.64	177.97	382.85	345.85	555.58	345.85	555.58	311.63	200.11	566.32	387.84	719.08	387.84	719.08	
17	Paid up Equity Share Capital (Face Value Re.1 each)	385.31	385.31	385.31	385.31	385.31	385.31	385.31	385.31	385.31	385.31	385.31	385.31	385.31	385.31	385.31	
18	Reserve Excluding Revaluation Reserve	-	-	-	-	-	1,078.89	-	1,078.89	-	-	-	-	-	-	-	
19 a)	Earnings Per Share (before extraordinary items Rs.)- Basic	0.52	0.47	0.46	0.99	0.90	1.44	0.90	1.44	0.82	0.53	1.49	1.03	1.91	1.03	1.91	
	Diluted	0.52	0.47	0.46	0.99	0.90	1.44	0.90	1.44	0.82	0.53	1.49	1.03	1.91	1.03	1.91	
b)	Earnings Per Share(after extraordinary items- Rs.)- Basic	0.52	0.47	0.46	0.99	0.90	1.44	0.90	1.44	0.81	0.52	1.47	1.01	1.87	1.01	1.87	
	Diluted	0.52	0.47	0.46	0.99	0.90	1.44	0.90	1.44	0.81	0.52	1.47	1.01	1.87	1.01	1.87	
PART 2																	
A PARTICULARS OF SHAREHOLDING																	
1 Public Shareholding:																	
	- Number of Shares	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	187,815,471	
	- Percentage of Holding	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	48.75%	
2 Promoters and Promoter group Shareholdings		197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	
	a) Pledged/Encumbered	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	NIL	
	- Number of Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
	- Percentage of Holding (as a % of the total share capital of the Company)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	
b) Non-encumbered		197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	197,491,733	
	- Number of Shares	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	
	- Percentage of Holding (as a % of the total shareholding of Promoter and Promoter Group)	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	100%	
	- Percentage of Holding (as a % of the total share capital of the Company)	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	51.25%	



[Handwritten signature]

B INVESTOR COMPLAINTS		Quarter ended 30.09.2014
	Pending at the beginning of the quarter	Nil
	Received during the quarter	1
	Disposed of during the quarter	-
	Remaining unresolved at the end of the quarter	1

Notes:

- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 31.10.2014.
- The Consolidated Financial Statements include Financial Statements of the subsidiaries Nova Pharmaceuticals Australasia Pty Ltd and Marksans Pharma (U.K.) Limited.
- The Company has paid dividend of ₹ 0.10/- (10%) per Equity Share of ₹ 1/- each face value and dividend of ₹ 7/- (7%) per 7% Redeemable Cumulative Preference Share of ₹ 100/- each face value for the financial year 2013-14.
- The Company is primarily engaged in a single business segment of Manufacturing & Marketing of Pharmaceutical Formulations.
- Previous year's figures have been re-grouped/re-classified, wherever necessary, so as to make them comparable with the current year's figures.

6 Statement of Assets and Liabilities:

	Particulars	Standalone as at		Consolidated as at	
		30.09.2014	31.03.2014	30.09.2014	31.03.2014
		UNAUDITED	AUDITED	UNAUDITED	AUDITED
A	EQUITY AND LIABILITIES				
	Shareholders' funds				
	(a) Share capital	520.31	520.31	520.31	520.31
	(b) Reserves and surplus	1,540.52	1,078.89	1,540.52	901.52
	(c) Money received against share warrants	-	-	-	-
	Sub-total-Shareholders' funds	2,060.83	1,599.20	2,060.83	1,421.83
	Minority Interest			73.54	66.36
	(a) Non-current liabilities				
	(b) Long-term borrowings	143.29	198.15	143.29	198.15
	(b) Deferred tax liabilities (Net)	18.68	18.68	23.44	23.42
	Sub-total - Non-current liabilities	161.97	216.83	166.73	221.57
4	Current liabilities				
	(a) Short-term borrowings	489.60	580.59	930.03	1,055.39
	(b) Trade payables	418.81	405.04	696.98	831.82
	(c) Other current liabilities	697.44	735.86	1,033.42	965.79
	(d) Short-term provisions	196.53	226.78	336.30	338.19
	Sub-total - Current liabilities	1,802.38	1,948.27	2,996.73	3,191.19
	TOTAL-EQUITY AND LIABILITIES	4,025.18	3,764.30	5,297.83	4,900.95
B	ASSETS				
	Non-current assets				
	(a) Fixed assets	672.60	668.14	1,432.59	1,456.49
	(b) Non-current investments	676.16	676.16	-	-
	(c) Long-term loans and advances	17.37	15.01	17.37	15.01
	Sub-total - Non-current assets	1,366.13	1,359.31	1,449.96	1,471.50
2	Current assets				
	(a) Inventories	565.01	556.09	1,142.95	1,025.89
	(b) Trade receivables	1,268.05	1,123.80	1,941.02	1,696.07
	(c) Cash and cash equivalents	390.04	333.74	471.35	469.47
	(d) Short-term loans and advances	435.95	391.36	292.55	238.02
	(e) Other current assets- Miscellaneous expenditure	-	-	-	-
	Sub-total - Current assets	2,659.05	2,404.99	3,847.87	3,429.45
	TOTAL ASSETS	4,025.18	3,764.30	5,297.83	4,900.95



For MARKSANS PHARMA LIMITED

MARK SILDANHA
Managing Director.

Place: Mumbai.
Date: 31.10.2014
www.marksanspharma.com